Mesoblast (MESO) Posts Q1 Loss of 5c/Share
Get Alerts MESO Hot Sheet
Join SI Premium – FREE
Mesoblast (NASDAQ: MESO) reported Q1 EPS of ($0.05), $0.30 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $395 thousand versus the consensus estimate of $3.69 thousand.
In line with previous guidance, the Company implemented operational streamlining measures during the quarter while achieving, and continuing to maintain progress towards, key milestones in its Tier 1 clinical programs.
For earnings history and earnings-related data on Mesoblast (MESO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SPS Commerce (SPSC) Tops Q3 EPS by 16c; Offers Guidance
- AptarGroup (ATR) Tops Q3 EPS by 5c
- BridgeBio Pharma Inc. (BBIO) Tops Q3 EPS by 14c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share